Chugai takes on two more Roche personalised medicine projects for Japan
This article was originally published in Scrip
Executive Summary
Chugai has acquired rights to another two molecules from parent Roche's pipeline for development and marketing in Japan, signing licensing deals for MetMab for non-small cell lung (NSCLC) and potentially other cancers and lebrikizumab for bronchial asthma as part of the group's 'personalised medicine' strategy.